Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

DUROS leuprolide enters phase III for prostate cancer

Oct. 10, 1997

Demeter BioTechnologies awarded grant for cancer therapeutics program

Oct. 10, 1997

Progress made on MMAC-1 research; Schering-Plough acquires rights to therapies

Oct. 10, 1997

Selective iNOS inhibitor inhibits tumor growth in mice

Oct. 10, 1997

New immunotherapy for metastatic tumors reported

Oct. 10, 1997

Cell pathway discovery holds potential for new anticancer treatments

Oct. 9, 1997

Sugen expands SU-101 clinical trials

Oct. 9, 1997

Results from phase I trials with ISIS-3521/CGP-64128A reported

Oct. 9, 1997

Pamidronate evaluated as potential therapy for bone cancer

Oct. 9, 1997

New antineoplastic cryptophycin derivatives

Oct. 9, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 7, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 7, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Science in 2025: the best of the rest
BioWorld Science
A review of 2025's noteworthy advances in medical research, including GLP-1 receptor agonists as anti-aging drugs, tumor-agnostic therapies and xenotransplants.